

MD Anderson provides world-class comprehensive gynecologic oncology care to women with gynecologic cancers. As international leaders in the field, we are driving innovations in cancer care through clinical trials, translational research, advanced surgical techniques and cancer prevention efforts. Additionally, our multidisciplinary team of experts are going beyond the disease with a commitment to help women by providing personalized treatment options and avoiding unnecessary procedures.

Cancers and benign conditions we treat

- Benign tumors
- <u>Cervical cancer</u>, including rare types, such as adenoid cystic carcinoma, clear cell carcinoma, carcinoid tumors, small cell/large cell/neuroendocrine, carcinomas and verrucous carcinoma
- · Cervical, vulvar and vaginal dysplasia
- <u>Fallopian tube cancer</u>, including rare types, such as leiomyosarcomas and transitional cell
- Gestational trophoblastic disease, including rare types, such as epithelioid trophoblastic tumor, hydatidiform mole, invasive mole and placental site trophoblastic tumor
- Hereditary cancer syndromes
- Ovarian cancer, including rare types, such as carcinosarcoma, clear cell carcinoma, low-grade serous tumors and variants, malignant germ cell tumors, mesothelioma, mucinous carcinomas, sex cord-stromal tumors and small cell carcinoma

- <u>Peritoneal cancer</u>, including rare types, such as carcinosarcoma, clear cell carcinoma, mesothelioma, mucinous carcinomas and small cell carcinoma
- <u>Uterine cancer</u>, including rare types, such as adenosarcoma, carcinosarcoma, endometrial stromal sarcoma, leiomyosarcoma, small cell/large cell/ neuroendocrine carcinomas and STUMP
- <u>Vaginal cancer</u>, including rare types, such as clear cell carcinoma, embryonal rhabdomyosarcoma, melanoma, verrucous carcinoma and yolk sac tumor
- <u>Vulvar cancer</u>, including rare types, such as aggressive angiomyxoma, Bartholin gland carcinoma, melanoma, Paget's disease, sarcomas and verrucous carcinoma



Making Cancer History®



Making Cancer History®

Where you send your patient first matters.

Ovarian Cancer

Ovarian cancer is the second-most common and the most lethal gynecologic malignancy. Although the median survival of ovarian cancer patients has increased in recent years, less than 30% survive long term. MD Anderson is leading research with our <u>Ovarian Cancer SPORE</u> program to overcome the intrinsic and acquired resistance of ovarian cancer cells that prevents current treatment options from increasing long-term survival.

In addition, our <u>Ovarian Cancer Moon Shot</u>* Program is focused on untreated high-grade serous ovarian cancer (HGSOC), recurrent HGSOC and low-grade serous ovarian cancer. Through this initiative, we plan to optimize upfront management in ovarian cancer surgery with our <u>Anderson Algorithm</u>, reduce the rate of recurrence through novel drugs and targeted therapy combination in an effort to prevent and/or reverse the emergence of resistance, and improve low-grade serous ovarian cancer outcomes by targeting chemoresistant tumors with molecular profiling.

Clinical services for ovarian cancer include:

- Innovative surgical methodologies for an <u>individualized surgical approach</u> to ovarian cancer
- Molecular profiling to identify <u>biomarkers</u> that help to tailor treatment strategies
- Clinical trial options using immunotherapy for advanced disease



Read about one ovarian cancer survivor's experience in **Cancerwise**.



Cervical Cancer

<u>HPV</u> is responsible for more than 90% of cervical and anal cancers; about 70% of vaginal, vulvar and oropharyngeal cancers; and more than 60% of penile cancers. MD Anderson's <u>HPV-Related Cancers Moon Shot</u>* Program is focused on expanding effective treatment approaches through developing targeted therapies specifically aimed at HPV E6 and E7 function, advancing strategies to understand the function of T cells that remain reactive to HPV peptides or antigens, and collecting and analyzing tumor samples to identify biomarkers.

Clinical services for <u>cervical cancer</u> include:

- Advanced surgical options, such as <u>abdominal radical hysterectomy</u>
- Lymphatic mapping and <u>sentinel lymph node biopsies</u> for early-stage cervical cancer
- Fertility-sparing techniques, such as radical trachelectomy



Watch Pedro Ramirez, M.D., discuss the first clinical trial to compare surgical options for women with early-stage cervical cancer.



Making Cancer History®

Where you send your patient first matters.

Uterine Cancer


Uterine cancer represents 3.6% of all new cancer cases in the U.S., and endometrial cancer is the most commonly diagnosed gynecologic cancer according to the National Cancer Institute. MD Anderson is committed to ending uterine cancer with our Endometrial Cancer SPORE research and treatment options. This translational research offers patients innovative clinical trials that are focused on the prevention and conservative treatment of endometrial cancer by developing novel therapeutics for advanced and recurrent endometrial cancer, incorporating molecular diagnostics into clinical decision-making, improving overall survival rates and evaluating mechanisms responsible for adaptive resistance to targeted therapies.

Clinical services for uterine cancer include:

- Conservative treatment options for early-stage endometrial cancer
- Comprehensive surgical staging with sentinel node mapping
- <u>Clinical trial</u> options with new therapies for uterine cancers



Read about one uterine cancer survivor's experience in **Cancerwise**.



Rare Gynecologic Cancers

Gynecologic cancers are often viewed as one large group, however rare gynecologic cancers represent approximately 50% of the total number of gynecologic tumors and each cancer type has its own treatment algorithm. Also, many of the gynecologic rare tumors overlap with other disciplines, such as sarcoma, melanoma, breast, thoracic, head and neck, and gastrointestinal ontologies. MD Anderson's Center for Rare Gynecologic Malignancies provides a centralized location for women to receive a sophisticated, multidisciplinary treatment approach that aims to improve patient outcomes, optimize standard of care treatment methodologies, and leverage the expertise of our providers with a specific disease.



Listen to Michael Frumovitz, M.D.,

discuss high-grade neuroendocrine cervical cancers, including small cell and large cell, for molecular alterations.



Making Cancer History®

Advanced treatment options for patients

- Clinical trials
- Enhanced Recovery After Surgery (ERAS), which improves the perioperative experience with shorter patient stays, patient-reported outcomes, and an 80% reduction in opioid usage
- Immunotherapy
- Molecular profiling

- <u>Surgery</u>, including minimally invasive procedures like robotic and laparoscopic, sentinel lymph node mapping, radical trachelectomy, loop electrosurgical excision procedure (LEEP), bilateral salpingo-oophorectomy and pelvic exenteration
- <u>Radiation</u>, including intensity-modulated radiotherapy (IMRT), brachytherapy, 3D conformal radiotherapy (3D-CRT), volumetric modulated arc therapy (VMAT)
- Targeted therapy

Support services

At MD Anderson, we strive to provide patients groundbreaking treatment options and integrated rehabilitation programs to give them the best chance at a high quality of life after cancer therapy. Clinical services available include:

- Care for gynecologic issues related to cancer treatment
- Evaluation, counseling and management of cancerrelated sexual issues
- <u>Lymphedema</u> treatment options, such as lymphedema bypass, vascularized lymph node transfer, suctionassisted lipectomy and/or noninvasive therapy
- Oncofertility services to preserve the ability to have children
- Plastic and reconstructive surgery for patients with pelvic malignancies to assist in structural and functional disorders after surgery and/or radiation
- Survivorship follow-up





Why MD Anderson

Cancer cannot wait.

At MD Anderson, we have developed new screening and diagnostic tools for pre-invasive and early-stage cancer detection. To learn more about gynecologic cancer screening guidelines, visit our <u>Clinical Practice Algorithms</u> page.

When physicians partner, patient's choice expands.

If your patient has an increased risk of gynecologic cancer due to family history, had an abnormal test result, or is in survivorship, we have multiple clinics available for your patient to get answers. Also, we are offering health care providers an opportunity to participate in our <u>Cervical Cancer Prevention Project ECHO</u> through teleconsulting and telementoring in rural and underserved communities.

Gynecologic Cancer Genetics Clinic

 Evaluation for suspected risk of inherited cancer predispositions, including BRCA1, BRCA2, Lynch syndrome and other mutations

High-Risk Ovarian Cancer Screening Clinic

 Risk assessment includes a clinical visit, transvaginal ultrasound and CA-125 blood test

Colposcopy Clinic


 Diagnosis and treatment of cervical, vaginal and/or vulvar dysplasia

Second Opinion Pathology

 Second opinion services on a full range of gynecologic pathology samples and assistance with determining if a tumor is localized or metastasized

Cancerwise

 Read more about <u>ovarian</u>, <u>cervical</u>, <u>uterine</u>, <u>vaginal</u>, <u>vulvar</u> and <u>fallopian tube</u> cancers through our blog, Cancerwise





Making Cancer History®

Connect with us.

A safer environment

Keeping our patients and workforce safe has always been our top priority. We continue to proactively implement measures to ensure the safety of patients on all our campuses. To learn more about our response to COVID-19, visit our Coronavirus Precautions page.

Oncology care team

For information about our gynecologic oncology faculty and staff, visit our directory.

Cancer center locations

When you refer to MD Anderson, your patients will receive the highest level of care in a safe, compassionate environment. We provide gynecologic cancer services at multiple locations across Houston, making it easy and convenient for your patients, including:

- Laura Lee Blanton Gynecologic Oncology Center (Texas Medical Center)
- MD Anderson Gynecologic Oncology Clinic at The Woman's Hospital of Texas
- MD Anderson League City
- MD Anderson in Sugar Land
- MD Anderson The Woodlands
- MD Anderson West Houston

Learn more about each of our locations and their offerings to find the most convenient one for your patient.

Patient referrals

Our Referring Provider Team is dedicated to assisting health care providers with the following:

- Referrals to any MD Anderson center or location
- Continuous follow-up on the status of referrals
- Answers to questions about patient access procedures
- Support with our online physician portal

Health Care Provider Resource Center

Physician portal

Our secure, HIPAA-compliant portal is available for health care providers to take an active role in managing patient care at MD Anderson. After creating a myMDAnderson for Physicians account, you can:

- Access patient appointment schedules
- Access transcribed patient reports and results
- Receive notifications regarding referral status and results
- Easily update your profile and contact information

Referring Provider Team

Phone: 877-632-6789

Fax: 713-563-2449

Monday-Friday: 8 a.m.-11 p.m. Saturday-Sunday: 8 a.m.-7 p.m.

physicianreferrals@mdanderson.org

Learn more about how to refer a patient.



